Patents by Inventor Jean-Francois Nicolas

Jean-Francois Nicolas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140162747
    Abstract: Legislations set constraints for free lotteries and other free games of chance. New services which can be charged to players are disclosed as a method, a system, and as the new business model that they create for games of chance and particularly free games of chance.
    Type: Application
    Filed: January 13, 2014
    Publication date: June 12, 2014
    Inventors: Jean-Francois Nicolas, Jean-Luc Cadranel
  • Publication number: 20140155139
    Abstract: The method consists in a new way of distributing advantages based on a new category of online game.
    Type: Application
    Filed: January 13, 2014
    Publication date: June 5, 2014
    Inventors: Jean-Francois Nicolas, Jean-Luc Cadranel
  • Patent number: 8309074
    Abstract: The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, Lactobacillus casei CNCM I-1518, which is present in Actimel®, for alleviating the symptoms of a delayed-type hypersensitivity reaction.
    Type: Grant
    Filed: January 20, 2006
    Date of Patent: November 13, 2012
    Assignee: Compagnie Gervais Danone
    Inventors: Jean François Nicolas, Catherine Goujon, Raphaëlle Bourdet-Sicard, Nathalie Rolf-Pedersen
  • Publication number: 20090081788
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Application
    Filed: December 18, 2007
    Publication date: March 26, 2009
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Publication number: 20090068149
    Abstract: The present invention relates to the field of probiotics. More particularly, the invention pertains to the use of a particular strain, Lactobacillus casei CNCM I-1518, which is present in Actimel®, for alleviating the symptoms of a delayed-type hypersensitivity reaction.
    Type: Application
    Filed: January 20, 2006
    Publication date: March 12, 2009
    Inventors: Jean Francois Nicolas, Catherine Goujon, Raphaelle Bourdet-Sicard, Nathalie Rolf-Pedersen
  • Publication number: 20080160616
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Application
    Filed: May 1, 2007
    Publication date: July 3, 2008
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 7309605
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: December 18, 2007
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 7271000
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: September 18, 2007
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 7214536
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: September 1, 2004
    Date of Patent: May 8, 2007
    Assignees: Institut Pasteur, University Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Publication number: 20060269522
    Abstract: A retroviral vector that eliminates cis-acting retroviral elements, which are not useful to and may cause problems for, an integrated provirus utilizes a recombination system, such as the bacteriophage P1 cre-lox recombination system. A gene of interest and a loxP site are inserted into a long terminal repeat, which is then duplicated. The enzyme cre is inserted between the long terminal repeats and combines them. The structure of the resulting provirus in the host genome is that of a single, long terminal repeat carrying a single copy of the gene of interest. Following infection, the retrovirus produces proviral structures having only a single long terminal repeat.
    Type: Application
    Filed: May 10, 2006
    Publication date: November 30, 2006
    Applicant: Institut Pasteur
    Inventors: Andre Choulika, Jean-Francois Nicolas
  • Publication number: 20050032223
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Application
    Filed: September 1, 2004
    Publication date: February 10, 2005
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 6833252
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: January 27, 2000
    Date of Patent: December 21, 2004
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 6822137
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: November 23, 2004
    Assignees: Institut Pasteur, Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Publication number: 20040097439
    Abstract: The present invention is concerned with modified polynucleotides derived from a native gene and having a reduced or increased number of epigenetic control motifs, at the nucleotide level, as compared to the native gene. These polynucleotides are useful to study, increase and/or reduce genes expression, and to improve DNA vaccination methods. The present invention also relates to methods of using these modified polynucleotides in in vitro and in vivo expression systems.
    Type: Application
    Filed: June 6, 2002
    Publication date: May 20, 2004
    Inventors: Jean-Francois Nicolas, Isabelle Henry, Andre Choulika
  • Publication number: 20030182670
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Application
    Filed: May 23, 2002
    Publication date: September 25, 2003
    Applicant: Institut Pasteur
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Publication number: 20030100528
    Abstract: The present invention is concerned with modified polynucleotides derived from a native gene and having a reduced or increased number of epigenetic control motifs, at the nucleotide level, as compared to the native gene. These polynucleotides are useful to study, increase and/or reduce genes expression, and to improve DNA vaccination methods. The present invention also relates to methods of using these modified polynucleotides in in vitro and in vivo expression systems.
    Type: Application
    Filed: June 6, 2002
    Publication date: May 29, 2003
    Inventors: Jean-Francois Nicolas, Isabelle Henry, Andre Choulika
  • Patent number: 6395959
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: May 6, 1996
    Date of Patent: May 28, 2002
    Assignees: Institut Pasteur, Universite Paris VI/Universite Pierre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas
  • Patent number: 6328940
    Abstract: Process for partial oxidation in a Claus furnace of at least one gas stream having hydrogen sulphide, and including the steps of: (a) injecting at least one gas stream including hydrogen sulphide and at least one oxygen-enriched gas stream into the Claus furnace, wherein each of the streams is injected at a speed of injection which is substantially parallel, and (b) controlling the speed of injection of the gas stream including hydrogen sulphide and the speed of injection of the oxygen-enriched gas stream such that the speeds have a ratio between 0.8 and 1.2.
    Type: Grant
    Filed: February 16, 2000
    Date of Patent: December 11, 2001
    Assignee: L'Air Liquide, Societe Anonyme pour l'Etude et l'Exploitation des Procedes Georges Claude
    Inventors: Ebrahim Djavdan, Jacques Koening, Jean-François Nicolas, Vincent Queudot, Olivier Charon
  • Patent number: 6200800
    Abstract: Retroviral vectors contain cis-acting viral elements for the expression, encapsidation, reverse transcription and integration of the retroviral genome nucleic acid sequence. However, these elements are not useful in the integrated provirus and may cause many problems. A retroviral vector is provided for eliminating most of the viral elements. This vector uses, among other things, the bacteriophage P1 Cre-lox recombination system. The 32-nucleotide loxP site is inserted into 3′LTR sequence U3 with the gene to be inserted into the cell. After loxP duplication using the LTR, the LTRs may be recombined by enzyme Cre. The structure of the resulting provirus in the host genome corresponds to a single LTR carrying a single copy of the gene to be inserted into the cell. If the Cre expression unit is inserted between the two LTRS, only single-LTR proviral structures are found following infection with the retroviral vector.
    Type: Grant
    Filed: May 11, 1998
    Date of Patent: March 13, 2001
    Assignee: Institut Pasteur
    Inventors: André Choulika, Jean-François Nicolas
  • Patent number: 5948678
    Abstract: An isolated DNA encoding the enzyme I-SceI is provided. The DNA sequence can be incorporated in cloning and expression vectors, transformed cell lines and transgenic animals. The vectors are useful in gene mapping and site-directed insertion of genes.
    Type: Grant
    Filed: July 20, 1998
    Date of Patent: September 7, 1999
    Assignees: Institut Pasteur, Universite Peirre et Marie Curie
    Inventors: Bernard Dujon, Andre Choulika, Arnaud Perrin, Jean-Francois Nicolas